Marshall Wace
NPCE icon

Marshall Wace’s Neuropace NPCE Stock Holding History

Marshall Wace’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$335K Sell
25,451
-5,580
-18% -$83.7K ﹤0.01% 2614
2025
Q4 		$479K Buy
+31,031
New +$415K ﹤0.01% 2254
2024
Q3 		– Sell
-32,045
Closed -$242K – 2820
2024
Q2 		$242K Sell
32,045
-26,313
-45% -$265K ﹤0.01% 2234
2024
Q1 		$770K Buy
58,358
+44,187
+312% +$630K ﹤0.01% 1755
2023
Q4 		$146K Buy
+14,171
New +$113K ﹤0.01% 2017
2021
Q3 		– Sell
-14,939
Closed -$355K – 3293
2021
Q2 		$355K Buy
+14,939
New +$347K ﹤0.01% 2270

Other funds holding NPCE

PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Marshall Wace's NPCE Position: Q1 2026 in Review

Marshall Wace reduced its Neuropace (NPCE) stake by 18% in Q1 2026, selling an estimated $83.7K and leaving 25,451 shares worth $335K. The position accounts for ﹤0.01% of the portfolio, ranked #2614.

Marshall Wace first reported a position in NPCE in Q2 2021 and has held it in 6 quarters since. The position peaked at $770K in Q1 2024. 113 funds tracked by Wall St. Rank hold NPCE as of Q1 2026.

  • Marshall Wace held 25,451 shares of Neuropace worth $335K as of Q1 2026.
  • Marshall Wace sold 5,580 Neuropace shares in Q1 2026, an estimated $83.7K.
  • Neuropace made up ﹤0.01% of Marshall Wace's portfolio in Q1 2026, its #2614 holding.
  • Marshall Wace first reported a position in Neuropace in Q2 2021 and has held it in 6 quarters since.
  • Marshall Wace's Neuropace position peaked at $770K in Q1 2024.
  • 113 funds tracked by Wall St. Rank held Neuropace as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.